🔎 Trials Near Me

Home › Immunoglobulin Light-chain Amyloidosis › Massachusetts

Pag-aaral pangklinika para sa Immunoglobulin Light-chain Amyloidosis sa Massachusetts

7 pag-aaral para sa Immunoglobulin Light-chain Amyloidosis ang naghahanap ng mga kalahok sa mga site sa Massachusetts.

Mga Lungsod sa Massachusetts

Opisyal na teksto ng pag-aaral (English)

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
  • Tufts Medical Center, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT06569147

Teclistamab-Daratumumab in AL Amyloidosis

  • Boston Medical Center, Boston
Nagre-recruitPhase 2
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT07110844

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

  • Research Site, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT07081646

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

  • Boston Medical Center, Boston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT06022939

Collection of Samples and Clinical Data From Patients With Amyloid Diseases

  • Boston University Cancer Research Center, Boston
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 1, 2025 · NCT00898235

Molecular Imaging of Primary Amyloid Cardiomyopathy

  • Brigham and Womens' Hospital, Boston
Nagre-recruit
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Nob 14, 2025 · NCT02641145

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

  • Tufts Medical Center, Boston
Nagre-recruitObservasyonal na pag-aaral
Edad 40 pataas · Lahat ng kasarian · Na-update Ago 6, 2025 · NCT06365060

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.